RT Journal Article
SR Electronic
T1 Cerebellar Ataxia With Anti-DNER Antibodies
JF Neurology - Neuroimmunology Neuroinflammation
JO Neurol Neuroimmunol Neuroinflamm
FD Lippincott Williams & Wilkins
SP e200018
DO 10.1212/NXI.0000000000200018
VO 9
IS 5
A1 Peter, Elise
A1 Do, Le Duy
A1 Hannoun, Salem
A1 Muñiz-Castrillo, Sergio
A1 Vogrig, Alberto
A1 Wucher, Valentin
A1 Pinto, Anne-Laurie
A1 Chounlamountri, Naura
A1 Zakaria, Walaa
A1 Rogemond, Veronique
A1 Picard, Geraldine
A1 Hedou, Julien-Jacques
A1 Ambati, Aditya
A1 Alentorn, Agusti
A1 Traverse-Glehen, Alexandra
A1 Manto, Mario
A1 Psimaras, Dimitri
A1 Mignot, Emmanuel
A1 Cotton, Francois
A1 Desestret, Virginie
A1 Honnorat, Jérôme
A1 Joubert, Bastien
YR 2022
UL http://nn.neurology.org/content/9/5/e200018.abstract
AB Background and Objectives There is no report on the long-term outcomes of ataxia with antibodies against Delta and Notch-like epidermal growth factor–related (DNER). We aimed to describe the clinical-immunologic features and long-term outcomes of patients with anti-DNER antibodies.Methods Patients tested positive for anti-DNER antibodies between 2000 and 2020 were identified retrospectively. In those with available samples, immunoglobulin G (IgG) subclass analysis, longitudinal cerebellum volumetry, human leukocyte antigen isotyping, and CSF proteomic analysis were performed. Rodent brain membrane fractionation and organotypic cerebellar slices were used to study DNER cell-surface expression and human IgG binding to the Purkinje cell surface.Results Twenty-eight patients were included (median age, 52 years, range 19–81): 23 of 28 (82.1%) were male and 23 of 28 (82.1%) had a hematologic malignancy. Most patients (27/28, 96.4%) had cerebellar ataxia; 16 of 28 (57.1%) had noncerebellar symptoms (cognitive impairment, neuropathy, and/or seizures), and 27 of 28 (96.4%) became moderately to severely disabled. Half of the patients (50%) improved, and 32.1% (9/28) had no or slight disability at the last visit (median, 26 months; range, 3–238). Good outcome significantly associated with younger age, milder clinical presentations, and less decrease of cerebellar gray matter volumes at follow-up. No human leukocyte antigen association was identified. Inflammation-related proteins were overexpressed in the patients' CSF. In the rodent brain, DNER was enriched in plasma membrane fractions. Patients' anti-DNER antibodies were predominantly IgG1/3 and bound live Purkinje cells in vitro.Discussion DNER ataxia is a treatable condition in which nearly a third of patients have a favorable outcome. DNER antibodies bind to the surface of Purkinje cells and are therefore potentially pathogenic, supporting the use of B-cell–targeting treatments.DNER=Delta and Notch-like epidermal growth factor–related; HLA=human leukocyte antigen; IgG=immunoglobulin G; mRS=modified Rankin Scale; PCA=paraneoplastic cerebellar ataxia